

REGISTERED No. M - 302  
L.-7646

**The Gazette**  **of Pakistan**

**EXTRAORDINARY  
PUBLISHED BY AUTHORITY**

---

---

**ISLAMABAD, MONDAY, JANUARY 28, 2019**

---

---

**PART III**

**Other Notifications, Orders, etc.**

GOVERNMENT OF PAKISTAN  
**MINISTRY OF NATIONAL HEALTH SERVICES, REGULATIONS AND  
COORDINATION**

**(Drug Regulatory Authority of Pakistan)**

**NOTIFICATION**

*Islamabad, the 21st January, 2019*

**No. F. 9-13/2016-DDC(P).**—In pursuance of sub-clause (vii) of clause (c) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with para 12(4) of the Drug Pricing Policy-2018, the Federal Government, on the recommendation of the Policy Board, is pleased to amend para 9 of the Drug Pricing Policy-2018 as under:

- (a) By inserting factor of 3.15 for calculation of maximum retail prices of locally manufactured Anti-T.B drugs in table of sub-para (2) of para-9 of the said Policy.

(231)

*Price: Rs. 5.00*

[134(2019)/Ex. Gaz.]

(b) Drug Pricing Committee may consider hardship cases of critically needed drugs on the basis of import prices of raw materials or finished drugs as per Letter of Credit established by the applicant by inserting a sub-para (6) in para-9 of the said Policy.

AMANULLAH,  
*Director, Costing & Pricing.*

EXTRAORDINARY  
PUBLISHED BY AUTHORITY  
ISLAMABAD, MONDAY, JANUARY 28, 2019  
PART III  
Other Notifications, Orders, etc.  
GOVERNMENT OF PAKISTAN  
MINISTRY OF NATIONAL HEALTH SERVICES REGULATIONS AND  
COORDINATION  
(Drug Regulatory Authority of Pakistan)  
NOTIFICATION  
Islamabad, the 23rd January 2019  
No. N-9-13016-DRC (I/P) - in pursuance of sub-clause (vii) of clause  
(c) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of  
2012) read with para 13(a) of the Drug Pricing Policy-2018, the Federal  
Government, on the recommendation of the Honey Board, is pleased to amend  
para 9 of the Drug Pricing Policy-2018 as under:  
(a) By inserting a factor of 1.15 for calculation of maximum retail price  
of locally manufactured Anti-B drugs in table of sub para (2) of  
para 9 of the said Policy.  
(231)